Research programme: ophthalmic anti-fungal therapeutics - SantenAlternative Names: Nova 21046
Latest Information Update: 29 May 2013
$50 / €47 *
At a glance
- Originator Novagali Pharma
- Developer Santen S.A.S.
- Mechanism of Action Sterol demethylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ophthalmic infections
Most Recent Events
- 29 May 2013 Discontinued - Preclinical for Ophthalmic infections in France (Ophthalmic)
- 11 Oct 2011 Novagali Pharma has been acquired by Santen Pharmaceutical
- 22 Jan 2008 Preclinical trials in Ophthalmic infections in France (Ophthalmic)